BVS vs MCK: fair value comparison
Bioventus Inc. and McKesson Corporation · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, BVS currently sits closer to the top of our ranking by discount to fair value. BVS carries the stronger quality grade.
| BVS | MCK | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $13.30 | $938.84 |
| 12-month range | $6.53–$15.26 | $725.17–$1,004.84 |
| Rank by discount to fair value | #67 of 108 Healthcare | #68 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BVS fair value analysis · MCK fair value analysis